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Background. The value of incremental peritoneal dialysis (PD) as a bridge to renal transplantation (Tx) has not been speciﬁcally
addressed. Methods. All consecutive Stage 5 CKD patients with at least 1 year predialysis followup, starting incremental PD or
HD under our care and subsequently receiving their ﬁrst renal Tx were included in this observational cohort study. Age, gender,
BMI, underlying nephropathy, residual renal function (RRF) loss rate before dialysis and RRF at RRT start, comorbidity, RRT
schedules and adequacy measures, dialysis-related morbidity, Tx waiting time, RRF at Tx, incidence of delayed graft function
(DGF), in-hospital stay for Tx, serum creatinine at discharge and one year later were collected and compared between patients on
incremental PD or HD before Tx. Results. Seventeen patients on incremental PD and 24 on HD received their ﬁrst renal Tx during
the study period. Age, underlying nephropathy, RRF loss rate in predialysis, RRF at the start of RRT and comorbidity did not diﬀer
signiﬁcantly.Whileondialysis,patientsonPDhadsigniﬁcantlylowerepoetinrequirements,serumphosphate,calciumxphosphate
product and better RRF preservation. Delayed graft function (DGF) occurred in 12 patients (29%), 1 on incremental PD and 11
on HD. Serum creatinine at discharge and 1 year later was signiﬁcantly higher in patients who had been on HD. Conclusions.I n
patients receiving their ﬁrst renal Tx, previous incremental PD was associated with low morbidity, excellent preservation of RRF,
easierattainmentofadequacytargetsandsigniﬁcantlybetterimmediateand1-yeargraftfunctionthanthoseobservedinotherwise
well-matched patients previously treated with HD.
1.Introduction
The feasibility and safety of incremental peritoneal dialysis
(PD) as a ﬁrst-choice renal replacement therapy (RRT)
and the good clinical outcome it oﬀers to well-motivated
stage 5CKD patients have been extensively reported [1–4].
This strategy involves elective timely start of PD with a
low dose, gradually increased afterwards to compensate
ongoing individual residual renal function (RRF) loss to
meet total (peritoneal plus residual renal) recommended
small solutes clearances adequacy targets [5]. It appears to
be a suitable home-based RRT modality, less intrusive on
patient’s social and active work schedules, which promotes
RRF preservation, vascular access sparing, and cost saving.
After the very encouraging extension of our preliminary
experience [3], this approach has become the standard of
practice at our institutions, enabling us to assess the value of
incremental PD as a bridge to renal transplantation, an issue
that has not been speciﬁcally focused upon to date.
2.SubjectsandMethods
All consecutive incident stage 5CKD patients attending our
advanced uremia clinic for at least one year, who then started
RRT with incremental PD or hemodialysis (HD) under our
care and subsequently received their ﬁrst renal transplant
(Tx) from January 2000 to December 2008, were included
in this observational cohort study. Age, gender, underlying
nephropathy, residual renal function (RRF, half-sum of urea
and creatinine urinary clearances) and RRF loss rate before2 International Journal of Nephrology
dialysis, comorbidities, RRT schedules, adequacy targets
(average of quarterly determinations of renal and dialytic
urea KT/V, Hb, epoetin weekly dose, serum calcium and
phosphate), dialysis-related morbidity, Tx waiting time, RRF
at Tx, incidence of delayed graft function (DGF, deﬁned
as need of dialysis in the ﬁrst week after Tx), in-hospital
stay for Tx, and serum creatinine at discharge and one year
later were recorded. Data were collected and summarized as
means ± SD, median ± interquartile range and proportions;
continuous variables were compared with the Student’s t-
test for independent samples when normally distributed, or
otherwise by the Mann-Whitney test; dichotomous variables
werecomparedwiththetwo-tailedFisher’sexacttest;relative
risk(RR)with95%conﬁdenceinterval(CI)foranuria(urine
volume <100mL/24 hours) at Tx and DGF was calculated
and compared between patients on incremental PD or HD
before Tx.
3. Results
Three hundred and twenty-seven patients with stage 5CKD
who attended the advanced uremia clinic at our institutions
electively started RRT under our care in the study period.
Modality choice in the whole cohort was determined by
patient’s preference in 78% of the cases; in 16% of the
cases, HD was preferred due to contraindications for PD;
in 6% of the cases, PD was chosen because of exhausted
vascular access option. The percentage of patient on PD was
21.1% overall. In all 106 subsequently wait-listed patients,
RRT modality selection was a patient’s choice; 30% of them
choose incremental PD. All the patients were followed up
by the same nephrology team while on RRT. Those without
obvious contraindications were then evaluated for renal
transplant suitability by one experienced nephrologist (M.
C.Comunian), who was responsible for listing and pre-
and post-Tx followup. During the study period, 59 patients
received a renal Tx; of these, 18 were not included in this
study because of unavailability of predialysis followup (n =
5), Tx other than ﬁrst (n = 6), combined kidney-pancreas
Tx (n = 5), or early Tx failure due to recurrent or de
novo glomerular disease (n = 2). Among included patients,
17 on incremental PD and 24 on HD received a renal Tx
after 28 ± 13 and 32 ± 13 months of RRT, respectively
(P = 0.2); all grafts were from deceased donors, except two
from living related donors in 2 patients on HD. Twenty-
six patients (63%) were transplanted in one of our regional
centers, the remainder in 7 other national referral centers,
with a similar distribution of PD- and HD-treated patients.
The demographic and clinical characteristics of the study
population at the start of RRT are summarized in Table 1.
Apart from a slightly higher female prevalence among
patients on incremental PD, no other diﬀerences were
found in age, body-mass index, comorbidities, underlying
nephropathy, CKD progression rate, and RRF at the start of
RRT between patients on incremental PD or HD. There was
noRRTmodalityswitchuntilTx.Mainadequacyparameters
during RRT are shown in Table 2.
Adequate small solute clearances and haemoglobin (Hb)
levels were maintained in both groups of patients, although
at the expense of a higher, and rapidly increasing, dose of
dialysis (see Supplementary Material available online at
doi: 10.4061/2011/204216) and epoetin in patients on HD.
Serum phosphate and calcium x phosphate product became
signiﬁcantly higher early in the course of RRT in patients
on HD and tended to worsen with time. Serum phosphate
was <5.9mg/dL in 76% of 155 quarterly determinations
in patients on incremental PD and in only 5% of 252
determinations in patients on HD; serum calcium x phos-
phate product was <55mg2/dL2 in 82% of 155 quarterly
determinations in patients on incremental PD and in 25%
of 252 determinations in patients on HD. A highly sig-
niﬁcant reduction of RRF loss rate from −0.97 ± 0.3t o
0.27 ± 0.4mL/min/month was observed in patients on
incremental PD (P<0.001), which was only marginally
the case in patients on HD (from −0.99 ± 0.48 to −0.77 ±
0.5mL/min/month, P = 0.06). At the time of Tx, 6 out of
17 patients on incremental PD against 19 out of 24 patients
on HD were anuric (P = 0.0086, RR 0.44, 95% CI 0.22 to
0.87, P = 0.019) (see Supplementary Material). Dialysis-
related morbidity was infrequent in this positively selected
cohort of CKD patients, being limited to ten peritonitis
episodesin8patientsonPD—correspondingtoacumulative
incidence of 0.25 episode per year at risk—and 4 vascular
access revascularization procedures in 3 patients on HD. The
immediate and medium-term outcome of renal Tx in this
cohort is depicted in Table 3.
TimeonRRTbeforeTxwasslightly,butnotsigniﬁcantly,
shorter for patients on PD; 12 patients, one on incremental
PD and 11 on HD, suﬀered DGF, needing three to eleven
dialysis sessions (median 6) after TX surgery; overall in-
hospital stay for Tx tended to be longer for patients on HD.
At discharge, serum creatinine was signiﬁcantly higher in
previouslyHD-treatedpatients,asitwasoneyearlater.While
all PD catheters had been removed within 16 weeks after Tx
(3 at the time of Tx surgery), 5 HD patients experienced
mildly symptomatic spontaneous thrombosis of the native
arteriovenous ﬁstula (AVF), the remainder still harbouring a
functional one after a mean followup of 46 ± 28 months. At
last followup (48±32 months for patients previously on PD,
41 ± 36 months for those previously on HD), 3 previously
HD-treated patients had returned to dialysis because of graft
failure after 15, 28, and 43 months, respectively. No patients
previously on PD has to date returned to RRT because of
graft failure.
4. Discussion
Even though when and how to start RRT is still a matter
of ongoing investigation and debate, in nonseverely uremic
CKD patients electively starting dialysis, the incremental
approach seems rationale and would be the preferred choice
[5, 6]. In this respect, incremental PD has some inherent
and logistical advantages over in-centre HD, being a usually
self-performed, home-based therapy, easier to accommodate
patient’s previous social and active work schedules, which
promotes vascular access sparing, longer retention of any
clinically relevant RRF, and health care costs saving [3, 5].
Most recent large observational studies comparing outcomeInternational Journal of Nephrology 3
Table 1: Demographic and clinical characteristics of the patients.
Gender Age, years BMI,
kg/m2
Underlying renal
disease
RRF loss rate in
predialysis,
mL/min/month
RRF at dialysis
initiation,
mL/min
Incremental PD
(n =17)
9F / 8M
(53%) 37 ±13 23 ±2
3A l p o r t
−0.97 ±0.34 6.9 ±1.1
2F S G S
2V U R
2I gA G N F
1S L E
1M CG N F
1 undeﬁned GNF
1D N
1 vascular disease
3 unknown
HD
(n = 24)
10 F/14 M
(42%) 43 ±14 23 ±2
3I gAG N F
−0.99 ±0.48 6.8 ±1.5
3 undeﬁned GNF
2M N
2V U R
2H U S
2A l p o r t
1A D P K D
1D N
1F S G S
1v a s c u l i t i s
6 unknown
P value 0.7 0.1 0.8 0.48 0.4
FSGS: focal segmental glomerulosclerosis; VUR: vescicoureteral reﬂux; SLE: systemic lupus erythematosus; MC GNF: mesangiocapillary glomerulonephritis;
DN: diabetic nephropathy; MN: membranous nephropathy; HUS: haemolytic uremic syndrome; ADPKD: autosomal dominant polycystic kidney disease;
GNF: glomerulonephritis; Ig A: immunoglobulin A.
Table 2: Main adequacy parameters during RRT.
Weekly
dialytic urea
KT/V at
start
Weekly
dialytic urea
KT/V at Tx
Time-
averaged
Hb, g/dL
Time-
averaged
EPO dose,
U/Kg/week
Time-
averaged Ca x
P, mg/dL
Time-
averaged
serum
phosphate,
mg/dL
RRF loss rate,
mL/min/month
Incremental PD
(n = 17) 0.69 ±0.21 .33 ±0.31 1 .9 ±0.9 112 ±33 50 ±45 .7 ±0.4 −0.27 ± 0.4
HD (n = 24) 2.5 ±0.5
∗ 3.3 ±0.3
∗ 12.3 ±0.9 199 ±58 58 ±46 .8 ±0.4 −0.77 ± 0.5
P value <0.0001 <0.0001 0.2 <0.0001 <0.0001 <0.0001 <0.0001
∗Daugirdas single-pool.
Table 3: Main TX outcome data.
Tx waiting
time, months
In-hospital stay
for Tx, days DGF n
Serum
creatinine at
discharge,
mg/dL
Serum
creatinine at
3m o n t h s ,
mg/dL
Serum
creatinine at
1 year, mg/dL
Incremental PD
(n = 17) 26 ±15 19 ±41 1 .3 ±0.31 .2 ±0.31 .14 ±0.3
HD (n = 24) 28 ±20 22 ±61 1 2 .1 ±0.91 .6 ±0.51 .96 ±0.9
P value 0.2 0.08 0.006 0.0013 0.0031 0.0016
DGF: delayed graft function.4 International Journal of Nephrology
of patients starting PD or HD as their ﬁrst RRT reported a
time-dependent advantage in favour of PD during the ﬁrst
1t o3y e a r s[ 7], which overlaps with the waiting time
for a deceased-donor Tx in this study. It may be thus
reasonably expected that patients scheduled to be timely
transplanted could beneﬁt the most from a “PD-ﬁrst”
policy. Furthermore, a low incidence of DGF in patients
on PD at the time of Tx has been consistently reported
in most large, registry-based studies [8–10]a n df o u n d
to portend a favourable impact on long-term graft and
patients outcomes [11, 12]. Our study demonstrated that
such results, and perhaps even better ones, can be achieved
with the incremental PD-dose strategy. Throughout their
timeonRRT,ourpatientsonincrementalPDshowedamore
desirable biochemical proﬁle and cost/eﬀective attainment
of adequacy targets than their HD counterpart, and we
stronglybelievethatbetterpreservationofRRFisakeyfactor
here. In carefully managed patients on HD, a RRF loss rate
similar to that commonly seen with PD has been reported
using biocompatible membranes [13] and an incremental
dialysis approach [14]. Unfortunately, this was not the case
in our patients, despite careful avoidance of overzealous
ultraﬁltrationandnephrotoxicinjuries,andtheuniversaluse
of biocompatible (mainly polysulfone) membranes. Early
Tx outcome was dramatically better in PD patients in this
study, even more than previously reported [8–10, 15], but we
acknowledge that the quite disappointing outcome of some
of our HD patients magniﬁed comparison in favour of PD.
DGF incidence and 1-year graft function, both regarded as
predictive of long-term graft and patient’s outcomes [10–
12], were substantially worse in our HD patients, despite
adopting the suggested policy of avoiding HD, and especially
“aggressive” ultraﬁltration, in the 24 hours preceding Tx
[16].Wepresentdatawiththemostcommonlyuseddialysis-
based deﬁnition of DGF, which has been criticized [17], but
even using “functional” rival deﬁnitions with possibly better
predictive power, the results in favour of patients on PD
remain signiﬁcant in ours as well as other studies [8, 18].
A further condition recently recognized to negatively
aﬀect outcome of patients on RRT and consistently reported
to be more frequent in HD patients is pulmonary hyper-
tension [19–21], which appears to be detrimental even with
regard to renal Tx [22, 23]. Interestingly enough, it was
found in 23% and 54% of our Tx-listed patients on PD and
HD, respectively, (P = 0.016), reversed after Tx in all but
three patients previously on HD and developed de novo in
af o u r t h . All these patients have had DGF, and their 1-year
graft function was signiﬁcantly worse than the rest of the
HD cohort. Pulmonary artery pressure, either before or after
Tx, inversely correlated with graft function in the whole RRT
cohort (data not showed). While no high level of evidence-
based guidelines on what to do with the AVF in successfully
transplanted patients exists [24], some attendant morbidity
cannot be excluded [25] and this issue may represent a
further overlooked argument in favour of PD prior to renal
Tx [26].
The present study has of course some obvious limita-
tions; ﬁrst of all the small number of patients included,
which induces caution in extrapolating results to larger
populations. The second is our inability to collect suﬃcient
data for a meaningful control of some donor and graft-
related factors presently regarded as having an impact on
early graft function, such as donor age, gender and cause
of death, cold and warm ischemia time, HLA mismatches,
and peak of PRA. Even if we cannot formally exclude a bias
due to the above-mentioned factors, systematic by chance
clustering of unfavourable ones in patients on HD (and/or
of favourable ones in patients on PD), large enough to
substantially aﬀect results, is quite unlikely. We acknowledge
that our results do not apply to pediatric patients and
might have been diﬀerent with a shorter or longer Tx
waiting time [27, 28]. Restricting the analysis to patients
who wait less than the median actual time in this cohort
of patients, however, did not abolish signiﬁcance in favour
of incremental PD, while, on the other hand, our Tx-
listed patients on incremental PD experienced an excellent
technique survival, with only 2 out of 32 (6.25%) switched
to HD because of PD failure after a median followup of
52 ± 23 months. Recently published, large, registries-based
studiesdidnotshowPDtojeopardisetheoutcomeofdialysis
patients remaining on the Tx waiting list, with the only
possible exception of those with the higher BMI [29, 30].
We conclude that, in this cohort of patients on RRT
receiving their ﬁrst renal Tx, previous incremental PD was
associated with low morbidity, excellent preservation of RRF,
easier and more cost/eﬀective management of uremia, and
signiﬁcantly better immediate and 1-year graft function
than those observed in otherwise well-matched patients
previously treated with HD. According to these results, we
believe that the incremental PD option should be oﬀered to
every suitable stage 5CKD patients who appears to be a good
candidate for renal Tx. We are committed to improve the
early outcome of Tx in our patients on HD.
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